ConductScience.org, home

Comparison · NCT00867048-deaths

Early ART vs Deferred ART: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Early ART vs Deferred ART: deaths from any cause. Trial comparisons, record NCT00867048-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00867048-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.02840.02240.036wilson
Risk in group 20.0360.02920.0443wilson
Risk difference, group 1 minus group 2-0.00765-0.01790.00253newcombe hybrid score
Risk ratio, group 1 over group 20.7880.5741.08log
Odds ratio, group 1 over group 20.7820.5641.08log
Number needed to treat, for one fewer death from any cause on Early ART than on Deferred ART131from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Early ART
Initiate ART immediately following randomization~All licensed antiretroviral medications: In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
662,325EG000
Group 2Deferred ART
Defer ART until the CD4+ count declines to \<350 cells/cu mm or AIDS develops~All licensed antiretroviral medications: In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
852,359EG001

Harm

What it counts
Total, all-cause mortality
Time frame
All-Cause Mortality assessed up to a median of 9.3 years. Serious Adverse Events were assessed for a median of 5.5 years

Source ClinicalTrials.gov

Trial

Title
Strategic Timing of Antiretroviral Treatment
NCT number
NCT00867048
Phases
PHASE4
Conditions
HIV Infection
Interventions
All licensed antiretroviral medications
Lead sponsor
University of Minnesota
Results first posted
2023-12-20

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00867048-deaths